Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of MedicineJoined Russell 3000 IndexStrong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK,...
-
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee...
-
SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing lossNo evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec...
-
RESEARCH TRIANGLE PARK, N.C., June 11, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
-
RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
-
PEDMARKTM granted Breakthrough Therapy and Fast Track Designations by FDAActively preparing for NDA submission later this yearStrong financial position with $26.7 million in cash and no debt RESEARCH...
-
RESEARCH TRIANGLE PARK, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
-
Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033)NASDAQ listing in September 2017Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt ...
-
RESEARCH TRIANGLE PARK, N.C., March 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
-
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique...